Innovative Industrial Properties Q2 2025 Earnings Call Transcript

Quartr
Provided by Quartr
August 7, 2025

Key Takeaways

  • Positive Sentiment: Strategic $270 million investment in IQHQ diversifies IIP’s portfolio beyond cannabis and is expected to be accretive to AFFO with a blended yield above 14%.
  • Negative Sentiment: Ongoing legal disputes with major cannabis tenants (Forefront Ventures, Gold Flora, PharmaCann) are creating uncertainty around asset recovery and lease enforcement.
  • Negative Sentiment: Second-quarter revenue declined 12% to $62.9 million and AFFO fell to $48.4 million ($1.71/share), primarily driven by tenant defaults.
  • Positive Sentiment: IIP’s balance sheet remains strong with $2.6 billion in mostly unencumbered assets, an 11% debt-to-assets ratio, over $190 million in liquidity, and 367,000 shares repurchased.
  • Positive Sentiment: Management highlighted improving life science market fundamentals and secured a right of first offer on 5 million+ sqft of IQHQ’s future asset sales to support growth.
AI Generated. May Contain Errors.
Earnings Conference Call
Innovative Industrial Properties Q2 2025
00:00 / 00:00

There are 15 speakers on the call.

Operator

Good day, everyone, and welcome to the Innovative Industrial Properties Second Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's remarks, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Eli Kanter, Director of Investor Relations.

Operator

Please go ahead, sir.

Speaker 1

Thank you for joining the call. Presenting today are Alan Gold, Executive Chairman Paul Smithers, President and Chief Executive Officer David Smith, Chief Financial Officer and Ben Regan, Chief Investment Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. Please refer to the documents filed by the company with the SEC, specifically the most recent reports on Forms 10 ks and 10 Q, which identify important risk factors that could cause actual results to differ from those contained in the forward looking statements. We are not obligated to publicly update or revise any forward looking statements whether as a result of new information, future events or otherwise.

Speaker 1

In addition, on today's call, we will discuss certain non GAAP financial information such as FFO, normalized FFO and AFFO. You can find this information together with reconciliations to the most directly comparable GAAP financial measure in our earnings release issued yesterday as well as in our eight ks filed with the SEC. I'll now hand the call over to Alan. Alan?

Speaker 2

Thanks, Eli. Good morning and thank you for joining our call. Yesterday, we announced our first expansion outside of the cannabis industry with a strategic investment in IQHQ, a leading private life science REIT. This investment underscores our conviction in the long term fundamentals of the life science industry and provides IIP a unique opportunity to accretively deploy capital while adding industry and tenant diversification to our portfolio and positioning us to continue driving growth and creating long term value for our shareholders. IQHQ was founded in 2019 and has raised over $4,000,000,000 of equity capital since inception.

Speaker 2

Its current portfolio, including both operational and under development properties, totals over 5,000,000 square feet with additional pipeline potential, all located in the leading and largest global life science markets in Boston, South San Francisco, San Diego, and the Golden Triangle in The UK. Within the overall life science real estate market, we anticipate improving fundamentals with new deliveries in 2025 trending down compared to prior years and continued deceleration in construction starts expected in the near term. In addition, life science fundraising in 2025 is on track to be its highest since 2021, further underscoring investors' confidence in the long term fundamentals of the industry. This investment at this entry point positions us to capitalize on these long term secular tailwinds. The total commitment of $270,000,000 is expected to be highly accretive to AFFO, carrying a blended yield exceeding 14%.

Speaker 2

Our investment includes $100,000,000 investment in IQHQ's revolving credit facility to be funded at closing and future funding of up to $170,000,000 invested in IQHQ preferred stock to be funded over time. We expect to fund these investments with a combination of cash on hand, draws from the company's revolving credit facility and future financing activities. While we continue to evaluate investment opportunities in the cannabis industry, this investment provides complementary growth opportunities to enhance our investment pipeline, including a right of first offer on all future asset sales by IQHQ, providing potential pipeline opportunities on over 5,000,000 square feet of leading life science real estate or IIP. Our management team brings decades of experience in the life science industry, most recently in BioMed Realty, giving us the expertise to leverage our existing platform to drive accretive growth for our shareholders. As we continue to execute on our plan and drive value within our cannabis portfolio, we are excited to announce this return to accretive growth with our investment in IQHQ.

Speaker 2

With that, I'll now turn the call over to Paul. Paul?

Speaker 3

Thanks, Alan. Good morning, everyone. We are very excited about the IQHQ opportunity we announced and the growth potential for IIP. At the same time, we remain proud of our position as a pioneering and leading provider of real estate to the regulated cannabis industry. Although the cannabis industry continues to face challenges, including persistent macroeconomic uncertainty and unpredictable regulatory backdrop, it is still forecasted to grow at a compounded annual growth rate of approximately 7% from 2024 to 02/1929, reaching $44,000,000,000 by 02/1929.

Speaker 3

As we noted on our last call, we are focused on optimizing occupancy across our portfolio to strengthen our tenant credit profiles and are actively pursuing all legal remedies available to enhance the performance of our real estate portfolio. I'd like to provide some additional color on our progress with each tenant. Forefront Ventures filed for bankruptcy protection in Canada and for voluntary receivership in Massachusetts with Opus Consulting Partners appointed as a receiver. In addition, we are in active discussions with The US receiver and bankruptcy trustee regarding the properties and related claims. We continue to work closely with outside counsel to protect our legal interests and pursue our rights under the leases.

Speaker 3

Gold Flora is currently in receivership. We have intervened in the proceeding to actively protect our legal interest and remain in ongoing discussions with the receiver regarding the receivership and sale process. We successfully worked with the receiver to terminate the lease on one asset previously leased to Gold Flora and are actively pursuing releasing opportunities. We will continue to monitor the sale process and provide updates as we are able. With respect to PharmaCann, we have commenced formal legal proceedings to regain possession of the remaining properties they continue to occupy, including cultivation facilities located in Illinois, New York, Ohio, and Pennsylvania, and five retail properties located in Colorado.

Speaker 3

We are working closely with local council to pursue all of our rights and remedies under the leases and related guarantees, including pursuing monetary claims. These legal processes vary by state and are subject to the timelines of local jurisdictions, which makes it difficult to estimate the timing for recovery of these properties. However, we are diligently working through these processes as efficiently as possible and will provide updates as developments occur. In regards to TILT Holdings, they have made regularly monthly partial rent payments since April and we continue to reserve all of our rights under the leases while working in good faith with TILT to reach a resolution with respect to their outstanding financial obligations in conjunction with the planned divestiture of their plant touching businesses. As TILT announced last month, they have entered into a strategic agreement with Merri Med in Pennsylvania, where Merri Med intends to assume day to day management of operations at our Pennsylvania asset commencing in September.

Speaker 3

We will continue to provide updates on TILT's progress as we are able. We are committed to providing updates on all our proceedings and expected timing as we navigate through this process. However, we are still in the early stages. While we are encouraged by growing bipartisan support for cannabis reform, we continue to operate in a federally constrained environment. Despite nearly 90% of Americans supporting legal medical cannabis according to Pew Research and a majority of Republicans backing reform, meaningful federal action remains elusive.

Speaker 3

Reclassification to schedule three would represent a critical first step, easing the tax burden on operators and improving access to capital. We continue to see signs of resilience and long term opportunity in The U. S. Cannabis market. Notably, is outperforming traditional consumer categories in volume growth, outpacing alcohol, tobacco and even beverages like bottled water and energy drinks, underscoring its staying power as a consumer product.

Speaker 3

At the state level, we are monitoring adult use legalization efforts in Florida and Pennsylvania. In Texas, while the medical program remains highly restrictive, Governor Abbott recently signed legislation increasing the number of licenses in the state from three to 15, adding qualifying conditions to the program and raising the cap on product potency. We are also very encouraged by the strong sales growth in Maryland, New York and Ohio, where adult use conversations and an expanding consumer base are driving double digit increases in sales. One of the most pressing challenges operators face is the persistent and growing threat of the illicit market. This is not just a matter of unlicensed operators undercutting legal businesses.

Speaker 3

It's a deeply entrenched transnational issue. Investigative reporting has highlighted the rise of international organized crime groups that have established a dominant presence in the illegal marijuana trade across The US. These networks not only undermine regulated markets, but are also linked to broader criminal activities, including money laundering, human trafficking and violence. Their operations exploit regulatory gaps, overwhelm local enforcement and jeopardize the safety and reputation of legitimate operators. Just last quarter, California alone seized nearly 185,000 pounds of illegal cannabis valued at $500,000,000 These figures underscore a fraction of the issue and the need for stronger coordinated enforcement efforts at both the state and federal levels.

Speaker 3

I'd like to now turn the call over to Ben to discuss our investment, disposition and leasing activity. Ben? Thanks, Paul. Despite the challenges of

Speaker 4

the current environment, we have continued to execute on multiple fronts within our existing portfolio. Year to date, we have closed on a $7,800,000 acquisition in Maryland, completed two dispositions totaling $10,800,000 in Michigan and California, and executed two new leases totaling 211,000 square feet also in Michigan and California. In addition, as Alan touched on, we closed on a new investment with IQHQ, a private life science REIT with large scale operating and development assets located in transit rich hubs within the top life science real estate markets in the world. The current portfolio is targeted to encompass over 5,000,000 square feet once all development projects have been completed with meaningful future development potential in the owned pipeline. Our investment into the revolving credit facility and preferred stock will sit senior to all common equity in IQHQ and at a discount to replacement costs of the underlying assets, providing strong risk adjusted returns.

Speaker 4

Looking ahead, our overall pipeline remains robust, including both cannabis investments and additional opportunities to deploy capital in the life science industry. As part of our IQHQ investment, IIP was granted a right of first offer for any future asset sales by IQHQ. As Alan mentioned, this ROFO alone provides for a potential pipeline of future acquisitions exceeding 5,000,000 square feet of Class A premier life science real estate. We will continue to pursue these opportunities selectively, focusing on the highest quality investments with the most attractive risk adjusted returns for our shareholders. We remain confident with the plan we have in place and the experienced management team we have to execute on that plan.

Speaker 4

And with that, I'll hand it over to David.

Speaker 5

Thank you, Ben. For the second quarter, we generated total revenues of 62,900,000.0, a 12% decrease from the first quarter of this year. The decrease was primarily driven by the tenant defaults we previously disclosed in March. This decline was partially offset by additional funding of building improvements that resulted in base rent increases and contractual rental escalations. Adjusted funds from operations for the second quarter was 48,400,000.0 or $1.71 per share, a decrease of 12% compared to the 2025, driven primarily by the same factors affecting revenue.

Speaker 5

Our balance sheet remains in excellent shape, backed by $2,600,000,000 in primarily unencumbered gross assets. We maintain a simple, low leverage capital structure with only two ninety one million dollars in fixed rate debt outstanding. We also finished the quarter with strong liquidity, exceeding $190,000,000 through cash on hand and an undrawn revolver, providing ample financial flexibility to fund future growth, including the IQHQ investment we announced yesterday. And we remain committed to maintaining a conservative financial profile, highlighted by a low debt to gross assets ratio of 11% and a robust debt service coverage ratio exceeding 15x. On the capital markets front, during the quarter we repurchased 367,000 shares of our common stock at a weighted average price of $53.98 per share for a total cost of $19,800,000 which we accretively funded through the use of cash on hand and preferred stock that we issued during the quarter.

Speaker 5

In summary, our continued financial strength is evident in our prudent balance sheet management, ample liquidity, and disciplined capital allocation. As we look ahead, we remain confident that our robust financial position will support ongoing growth and deliver lasting value for our shareholders. With that, we thank you for joining the call and would like to open it up for questions. Operator, could you please open the call for questions?

Operator

Thank you. And ladies and gentlemen, at this time, we will now begin the question and answer session. And our first question today will come from Tom Catherwood with BTIG. Please go ahead.

Speaker 6

Thanks and good morning everybody. So I recognize the benefit the IQHQ investment can have for IAP's earnings and growth. That said, Life Science real estate still faces challenges and IQHQ has dealt with headwinds of its own. Can you walk us through the real estate investment case specifically for IQHQ? What is the business plan?

Speaker 6

How is the company overcoming challenges? And why is now the right time to invest in this specific company?

Speaker 7

Tom, we certainly can. But I just want to back up and just remind we didn't make an investment in the real estate. We made investment in an operating company that's invested in the life science sector along with having the opportunity to take advantage of the what's going on in the AI industry and the demand from AI software type companies who are looking for high quality real estate. Now, so again, we didn't invest in life science real estate. We believe from our expertise and historical knowledge that the life science industry, yes, is at an inflection point.

Speaker 7

It is had a very difficult three and a half, almost four years. And those owners of existing life science real estate have difficult time. We believe that there is a that the industry is has an opportunity to recover and that recovery has begun. And that valuations are still extremely low are starting to move in a very positive way. As a financial investment, our investment in IQHQ is was very well thought out, very well researched.

Speaker 7

It follows our, I think, very simple business plan of investing in sale leasebacks in the for the cannabis industry. We have made financial investments in a revolving credit facility and future commitments in a preferred the preferred series in IQHQ. I mean, I think I might the capital stack let me turn that over Ben to really talk about IQHQ's capital stack and where we fit within that capital stack.

Speaker 8

Yes. Sure. Thanks, Alan. Hey, Tom. Yes, we believe on top of this being an accretive transaction as you mentioned that it is a very safe secure investment and that we sit in front of the approximately $4,000,000,000 in equity that IQHQ has raised since inception.

Speaker 8

We believe that our spot in the capital stack represents a material discount to replacement costs. There's the property level debt and then we are the most secure position behind that within the capital stack again ahead of the $4,000,000,000 that IQHQ has raised.

Speaker 6

Okay. And then specifically on IQHQ and what this money goes towards and kind of the business plan for them. What does this get them to? And what was it that attracted you to that? There's a missing piece where I get the broader recovery in the sector that we're looking for and we see the green shoots there.

Speaker 6

But what was it about IQHQ's opportunity specifically that you thought this capital was useful for?

Speaker 7

Yes. Well, so specifically because of our insight or unique knowledge and expertise with IQHQ and with the life science industry, we and our due diligence of researching the markets that they're in, we believe that IQHQ's portfolio is well positioned to take advantage of the AI demand and the what we believe future demand for the life science industry. Now what this capital provides this capital along with other capital has been provided to IQHU gives them the ability to one complete their existing developments two complete the lease up of a very strong and high quality portfolio that are located in some of the best markets in for the life science sector and even for the AI tech boom. And gives them the ability to do those things and the time to accomplish that goal. And provides while all that's occurring and while they're succeeding provides a very attractive accretive return to IIP and IIB shareholders.

Speaker 6

Got it. I appreciate those details, Alan. And then last one for me. When this investment opportunity arose, how were potential conflicts of interest identified and reviewed to ensure the transaction didn't create risks for IIPR shareholders outside of normal course of business investment risk?

Speaker 7

Well, first there's an assumption that there were or that conflicts existed. But secondly, the IIP used a very focused and logical and methodology to by employing a special committee where the committee members had no interest in IQHQ. Then after that special committee reviewed the analysis and the diligence prepared by the team and outside counsel then that was then brought to the Board. And then the Board the Board members that had de minimis or no interest in IQHQ voted on this transaction and unanimously approved it because of its unique way it helps IIP. It is a very accretive transaction.

Speaker 7

It's a transaction that provides current cash flow to IIP shareholders and it diversifies our tenant exposure and our industry exposure at a time when we are looking to access the broader capital markets for a variety of different uses. And it gives us the ability to drive earnings growth in the future.

Speaker 6

Got it. Appreciate your answers, Alan. Thanks everyone.

Operator

And our next question will come from Bill Kirk with MKM Partners. Please go ahead.

Speaker 9

Hey, thank you. Good afternoon everybody. On the IQHQ, I'm trying to think of like the opportunity cost for the capital. And at a current level today, your dividend yield on your stock would be I think above 16%. So if you think that dividend level is safe, wouldn't the $270,000,000 get a better return buying back shares versus the estimated 14% in the IQHQ structure?

Speaker 7

Well, that's really easy to say when you look in the rearview mirror. Last week, two weeks ago, IIP shares weren't trading at 16%. So and we don't believe that. We believe that market volatility that occurs on a day to day basis isn't the way to run your business. We look at our overall cost of capital.

Speaker 7

And our overall cost of capital includes our access to a variety of different capital from not only our preferred and our debt and our credit facility, but also our common shares and what the expected return our investors are expecting from their common shares. So on a combination of all that, we believe this to be a very highly accretive transaction, especially when you consider that we're using capital that has been sitting and earning 3%, 4% and is now has the opportunity to earn in that average of 14%, very accretive.

Speaker 9

And then as a follow-up, what's the flexibility on the timing or I guess the commitment to the preferred portion of the investment?

Operator

Like, is is do you have

Speaker 9

the ability to, you know, pick when those those tranches are made? Do you have the ability to reduce size, increase size? What's the flexibility there? Because that 16% isn't rearview mirror anymore. It's it's it's today.

Speaker 7

So well, you know, what and if it's different tomorrow, it could be could be completely different tomorrow and so on and so forth. But to answer your question, look, we have a great deal of flexibility. We've designed the investment in the Series G to reflect what we believe will be our ability to raise capital over time. David, do you want to elaborate on that?

Speaker 10

Yes. And I think just on the funding mentioned that will occur between now and second quarter twenty twenty seven. But back to one of the points of the deal that we noted is we believe with accessing this new real estate market that has been along in the REIT space for a long time and that will improve overall access to equity and debt capital, as a result of that, just because it's non cannabis new sector. All of you on this call today are familiar with life science real estate. It's been around a very long time.

Speaker 9

Okay. Thank you, guys. Thank you for the color.

Operator

Thanks, Bill. Thank you. And our next question will come from Aaron Grey with Alliance Global. Please go ahead.

Speaker 11

Hi. Thank you for the time and the questions here. Just sticking on the question of IQHQ. So regarding the decision there to diversify some capital away from cannabis, can you maybe speak to how that decision came as it relates to the dividend, right? So we know that there has been a hot topic for you guys as it relates to the AFFO.

Speaker 11

And you mentioned how this really helps to accelerate some of the earnings that you'll be able to generate. So how that timing came into play and particularly through the lens of uncertainty regarding some of the defaults that you've had with some of the cannabis properties and when those earnings will come back? Thank you.

Speaker 7

Yes. Thank you. I mean, I think that's a really good question because I think as Paul has noted many times, we over the last eighteen, twenty four months we've been evaluating what's been going on within the industry. We have indicated to our shareholders that we've been looking at other investment opportunities outside of cannabis. And so we've been strategically evaluating different transactions and opportunities.

Speaker 7

And this opportunity came about. And it appeared to provide what we were looking for, a strategic investment that was of size that had the current income and the overall yield that met our what we believed our high cost of capital was and is. And so that began the process for us to continue to evaluate it. And as we spent more time diligent doing the diligence and understanding where we would be in the capital stack and how flexible the investment it became obvious to us that it was something that we should seriously consider. Lost my train of thought or lost the balance of your question because you another important part of your question.

Speaker 7

It was the The dividend. So we believe that and we believe that we needed more time to work through the underlying issues in the cannabis sector in general and specifically those major tenants that have had defaults and then to be able to reposition those assets that we are seeking to have returned to us in way that will be to the benefit of IIP and to reaccelerate our revenue growth. As you can see from our from what Ben has said, we've already released assets, a couple of assets in Michigan and Pennsylvania and continue to have great insight as to how to be able to reposition the assets that we will be taking back from those tenants and or restructuring with those tenants.

Speaker 11

Thanks for that commentary. That's helpful. Second question for me just regarding some of the defaults particularly PharmaCann. I know you gave some color on your prepared remarks. But just you previously noted, right, that they had debt maturing June 2025.

Speaker 11

So any color in terms of how specifically that's impacting the process in terms of the communication and how that could evolve given that they did have debt that was coming due two months ago or on June 30? Thanks.

Speaker 12

Yes. This is Paul, Eric. I think right now we're focused on recovering the assets from PharmaCann. We're very aggressively pursuing our eviction cases. We're getting no indication from PharmaCann that they will be in a position to anyway amicably resolve the debt they owe us for back rents and future rents.

Speaker 12

So we're laser focused on recovering those properties and releasing to qualified operators. So what happens with Pharmacons debt coming due is quite frankly not on our radar.

Speaker 11

Okay, great. Thanks. That's helpful. I'll jump back in the queue.

Operator

Thanks, Eric. And our next question will come from Alexander Goldfarb with Piper Sandler. Please go ahead.

Speaker 13

Hey, good morning out there. So I have a few questions here. First, Alan, obviously, you were critically involved with IQHQ as a company. I believe you left a few years ago. Just trying to understand the opportunity now.

Speaker 13

You guys are obviously enthusiastic about the rebound of IQHQ. And just want to know what's different now versus when you stepped away from the company a few years ago?

Speaker 7

Well, a few years ago, things I I want to be very careful because it is a private company and there was a lot going on when I stepped away personally and with the organization itself. Since I've departed that organization, they've made significant changes to the Board, to the governance structure, to management at the company. And all I think to the benefit of the potential success for IQHQ.

Speaker 13

Okay. And then you guys said that you're looking at this as an investment not operating the assets, but you also mentioned a ROFO to potentially acquiring the assets if they trade. And presumably there's a lot of CapEx that's needed to lease up these developments. So a two parter there. One is, it sounds like you are underwriting the potential of operating these assets.

Speaker 13

And two, does IQHQ have the capital required to fit these buildings out and lease them up?

Speaker 7

Well, to the second one, do they have the capital? Yes. They do have the capital depending on the timing tenant and the quality of that tenant and the length of the lease and on and on and on. There's many, many factors that IQHQ has to evaluate. And on the same thing, you're talking about right of first offer, which just gives us the ability to have insight as to when and if they try to sell an asset so that we can make sure that we're protecting our investment in the company.

Speaker 7

But if indeed the transaction were going to trade at a yield that would be attractive for IIP with a very strong tenant in well leased, I mean, I think financially if we had a very attractive high yielding strong tenant asset, I would think you would want us to look at it and evaluate it very carefully and see if it made sense for IAP shareholders to capitalize. And I think that's what we would do.

Speaker 13

Okay. And then the final question is, Paul, at the start of your comments, you talked about the competition in cannabis. Certainly, know about the illicit market, the gray market, but you mentioned sort of the global cartel market, which I guess we all would know, but you mentioned it more prominently. Big picture, given the debt issues the industry is facing for refinancing over the next twelve months and obviously this investment in IQHQ, are you saying that your thoughts on future investment in cannabis are no longer what you guys originally thought they would be? Or were you just mentioning the global cartel thing is sort of one of the generic headwinds that the industry is facing.

Speaker 13

I just want to know if it's more of a generic headwind versus, hey, you know what, the business case for cannabis isn't quite what we thought it was a few years ago. And therefore, you're going to see we're going to see you guys shift more away from cannabis into other sorts of real estate?

Speaker 12

Right. So Alex, I think with regard to the combination about the Chinese illegal growth, that's mentioned is just another factor in the overall illicit competition we have for the licensed operators. It's not a game changer. It just hit the news I think as far as the ICE raids in California some of the Chinese issues came up. So that's just another leg.

Speaker 12

And we are I want to make it clear that we are still committed to the cannabis industry. We are the leading providers of capital and we'll remain that way. I think we have telegraphed explicitly in our last couple of calls that there's not that many opportunities currently in the cannabis field. So being good stewards of capital, we felt it was appropriate to look at alternative investments, which we did for quite a while. Over a year we've been evaluating different opportunities.

Speaker 12

That's how we got to the IQHQ opportunity and looked at it extremely objectively and from square one and committed a great deal of diligence used outside counsel. And we came to the conclusion unanimously that this was the best opportunity to invest in something outside of cannabis. But we are still believers in the cannabis industry. We I talk about the projected growth. It is as I mentioned, it's outselling other beverage products.

Speaker 12

It's going. Right now, it's challenged. But rather than just sit on our hands, we thought it was appropriate and duty owed to our shareholders to use this capital appropriately and accretively. So that's what we're doing.

Speaker 13

So is this more of a temporary side like not side investment, but temporary non cannabis investment? Or we should expect more non cannabis investments?

Speaker 7

Well, think that at this point, we're going to see how things play out. We have a lot of things left on left to do including to work through the assets that we are going to be taking back from some of our tenants and hoping that the industry, the cannabis industry has some positive recovery news. And we're going to work through that first before we make before we go to the do anything else differently than what we've already done.

Speaker 13

Okay. Thank you very much.

Operator

Thanks, Alex. Our next question will come from Merrill Ross with Compass Point. Please go ahead.

Speaker 14

Hi, thank you for taking my question. Wanted to why you didn't make an investment given your expertise, an investment separately in a life sciences property or outright or do a joint venture with IQHQ. Why was this structure of a revolver and a preferred plus warrants more attractive than directly making your own investment?

Speaker 7

So the overall yields of or the current yields of life science transactions, if they were going to trade and assets that have that are well leased, those yields are significantly would be significantly below our current cost of capital. And investing in this way allowed us to have a very accretive transaction. And so that's why we went down this path. And I think because of the how difficult the life science industry right now and the overall operational expertise of operating a life science asset is something that I think is best suited for a company such as IQHQ. We've we went down this path and we believe we've structured a very opportunistic and high quality secure transaction that will provide, think, very accretive returns for IIP and IIP shareholders.

Speaker 14

Thank you. And to follow-up, can you disclose the current cash yield on the revolver?

Speaker 7

I mean, the current cash yield on our on the investment is north of a 10%.

Speaker 14

That excludes the preferred and warrant?

Speaker 7

No, it's a combination of the both.

Speaker 14

Thank you.

Operator

And this will conclude our question and answer session. I'd like to turn the conference back over to Alan Gold for any closing remarks.

Speaker 7

Thank you. And I would like to thank our shareholders for their continued support. Thank the team for your good and hard work. And with that, we'll end the call. Thank you.

Operator

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines at this time.

Powered by Quartr